Skip to content
    Boxer Capital of the Tavistock Group logo

    Boxer Capital of the Tavistock Group

    San Diego, California, United StatesFounded 2005
    www.boxercap.comLinkedIn
    Biotech & Life Sciences

    Boxer Capital is a San Diego-based biotechnology investment firm and the life sciences investment arm of Tavistock Group, the family office of Joe Lewis. Founded in 2005, it invests across the entire drug development lifecycle in specialized and precision medicine companies across both private and public markets.

    58% of their portfolio is in Biotech & Life Sciences. They made 3 investments in the last 12 months. Their most common stage is series-b (44% of deals). Average disclosed round size is $156.3M (across 50 rounds with reported amounts).

    Find people at Boxer Capital of the Tavistock Group on Goldilocks AI

    Portfolio

    41

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    3

    Team

    DN

    Dominik Naczynski

    Managing Director

    IL

    Ivan Lieberburg

    Managing Director

    NZ

    Norman Z.

    Managing Director

    AJ

    Alec Jones

    Senior Associate

    PH

    Peter Harwin

    Senior Associate

    TH

    Tony Huang

    Biotech Investing

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    52 investments
    CompanyRoundAmountDate
    Incyclix Bio logoIncyclix BioSeries B$5MApr 2026
    Mirador logoMiradorSeries B$250MJan 2026
    Mirador Tx logoMirador TxSeries B$250MJan 2026
    MMirador TherapeuticsUnknown$250MJan 2025
    Mirador Tx logoMirador TxSeries B$250MJan 2025
    Halda logoHaldaSeries B$126MAug 2024
    Alterome Therapeutics logoAlterome TherapeuticsSeries B$35MApr 2024
    AAlteromeSeries B$132MApr 2024
    Mirador Tx logoMirador TxUnknown$400MMar 2024
    Asher Bio logoAsher BioSeries C$55MJan 2024
    HHalda TherapeuticsSeries B$126MJan 2024
    Alterome Therapeutics logoAlterome TherapeuticsSeries B$132MJan 2024
    AAsher BiotherapeuticsSeries C$55MJan 2024
    Seismic logoSeismicSeries B$121MDec 2023
    Flare Therapeutics logoFlare TherapeuticsSeries B$123MMar 2023
    Seismic Therapeutic logoSeismic TherapeuticSeries B$121MJan 2023
    SpringWorks Therapeutics logoSpringWorks TherapeuticsUnknown$225MJan 2022
    LLusaris TherapeuticsSeries A$60MJan 2022
    Alterome Therapeutics logoAlterome TherapeuticsSeries A$64MJan 2022
    Shoreline Biosciences logoShoreline BiosciencesSeries D$140MNov 2021
    AAsher BiotherapeuticsSeries B$108MSep 2021
    Theseus Pharmaceuticals logoTheseus PharmaceuticalsSeries B$100MApr 2021
    Asher Bio logoAsher BioSeries A$55MMar 2021
    AAsher BiotherapeuticsSeries A$55MMar 2021
    Century Therapeutics logoCentury TherapeuticsSeries C$160MMar 2021
    Page 1 of 3

    Top Co-Investors

    RA Capital Management18 shared
    OrbiMed18 shared
    The Invus Group, LLC17 shared
    Alexandria Venture Investments12 shared
    Nextech Invest Ltd.10 shared
    Logos Capital10 shared
    Canaan Partners9 shared
    ARCH Venture Partners9 shared
    Wellington Management9 shared
    Third Rock Ventures9 shared
    Farallon Capital Management9 shared
    Venrock Healthcare Capital Partners8 shared
    BVF Partners L.P.6 shared
    Casdin Capital6 shared
    Fidelity Management & Research Company6 shared
    GV5 shared
    Perceptive Advisors5 shared
    Cormorant Asset Management5 shared
    Vivo Capital5 shared
    Pontifax5 shared

    Last updated: 7 October 2026